drugset / Trial / NCT01042041
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: This phase I trial is studying side effects and best dose of sorafenib tosylate when given together with chemoembolization in treating patients with unresectable liver cancer.
Timeline
- Start
- 2009-09
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Other |
| Subject | Doxorubicin | Other / unclassified | — | Other |
| Subject | Mitomycin C | Other / unclassified | — | Other |
| Subject | Sorafenib | Small molecule | — | Oral |